Key Takeaways
CMBC Securities gave BeiGene a “Buy” rating after the biotechnology company’s first-quarter 2026 revenue and profits surpassed expectations, driven by strong global sales of its cancer treatment zanubrutinib.
The bank’s research report highlighted the drug’s superior long-term clinical data compared to competitors and a robust pipeline of new treatments as key reasons for the positive outlook. While a specific price target was not disclosed, the firm cited the stock’s valuation as a key opportunity for investors.
CMBC forecasts that BeiGene’s net profit will grow at a compound annual rate of 42 percent between 2026 and 2028. The bullish rating was based on zanubrutinib’s expanding market share and the company’s progress in advancing multiple new drugs through clinical trials, which are expected to produce a steady stream of catalysts.
The rating comes as BeiGene and its partner, Jazz Pharmaceuticals, approach a critical milestone. The US Food and Drug Administration is expected to make a decision on the approval of their drug zanidatumab for treating gastroesophageal adenocarcinoma by its August 2026 PDUFA date. According to company filings, BeiGene is in line to receive significant milestone payments from partners pending regulatory approvals.
The strong performance of zanubrutinib and the upcoming regulatory decision for zanidatumab signal a period of significant growth for BeiGene. Investors will be closely watching the FDA’s decision in August as the next major event for the company.
This article is for informational purposes only and does not constitute investment advice.
